Prader-Willi Syndrome Drug Receives a Resounding ' No ' from FDA Advisory Panel Prader-Willi Syndrome Drug Receives a Resounding ' No ' from FDA Advisory Panel

An FDA advisory panel has voted overwhelmingly against a new drug application for intranasal carbetocin, intended to treat symptoms associated with Prader-Willi Syndrome.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Psychiatry News Source Type: news